Friday February 8, 2019 0 comments
ENGLEWOOD -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced its common shares have been approved to list on the Nasdaq Capital Market and is expected to begin trading under its existing symbol (ZYXI) on Feb. 12.
"We are excited to reach this important milestone for Zynex,” said Thomas Sandgaard, Zynex founder, chair and CEO.
“We have made significant progress over the past several years and uplisting to Nasdaq will help us communicate our story to a broader audience. We are now better positioned to attract institutional investors, which will fundamentally enhance the value of our company.”
Founded in 1996, Zynex markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients.
Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, visit: www.zynex.com.